-
Mashup Score: 92024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension - 7 month(s) ago
The European Society of Hypertension (ESH) reported in 2023 its current Guidelines for the management of arterial hypertension [1]. Following their aim to summarize the best available evidence for all aspects of hypertension management, the Task Force of the 2023 Guidelines generated a comprehensive document covering almost 200 pages including 1736 references [1]. This document thus provides a valuable and comprehensive source of information for hypertension management. However, due to the length of the text and its complexity, not only primary care providers (e.g.
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 92024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension - 7 month(s) ago
The European Society of Hypertension (ESH) reported in 2023 its current Guidelines for the management of arterial hypertension [1]. Following their aim to summarize the best available evidence for all aspects of hypertension management, the Task Force of the 2023 Guidelines generated a comprehensive document covering almost 200 pages including 1736 references [1]. This document thus provides a valuable and comprehensive source of information for hypertension management. However, due to the length of the text and its complexity, not only primary care providers (e.g.
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
https://t.co/qxrXI4SpSf
-
-
Mashup Score: 642024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension - 7 month(s) ago
The European Society of Hypertension (ESH) reported in 2023 its current Guidelines for the management of arterial hypertension [1]. Following their aim to summarize the best available evidence for all aspects of hypertension management, the Task Force of the 2023 Guidelines generated a comprehensive document covering almost 200 pages including 1736 references [1]. This document thus provides a valuable and comprehensive source of information for hypertension management. However, due to the length of the text and its complexity, not only primary care providers (e.g.
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
2024 #ESH clinical practice guidelines for the management of arterial hypertension - European Journal of Internal Medicine https://t.co/KHaQ1l2661
-
-
Mashup Score: 52Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease - 7 month(s) ago
Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease, is a spectrum of liver injury characterized by increased hepatocellular fat deposition with different histological degrees of severity. Simple fat accumulation above 5 % (MASL – Metabolic-dysfunction associated steatotic liver) in the absence of features of liver damage is a relatively benign, non-progressive disease. On the contrary, a superimposed liver inflammation and apoptosis (MASH – Metabolic-dysfunction associated steatohepatitis), in particular when associated with increased scar tissue deposition, is a hallmark of progressiveness of MASLD with a relevant impact on prognosis and disease burden [1].
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
RT @scottisaacsmd: Dietary and pharmacological treatment in patients with #MASLD. https://t.co/GC9NyPEXB5 https://t.co/rTcDY4IfJg
-
-
Mashup Score: 1372023 ESH Guidelines. What are the main recommendations? - 8 month(s) ago
Generally, Clinical Practice Guidelines (CPG) are evidence-based recommendations, presented as summaries of the best available literature, which are aimed to assist doctors and other health care professionals in the management of patients with a given disease. In the field of hypertension, as well as in other fields, the recommendations in CPG should be easy to implement in routine clinical practice [1]. CPG are intended to provide guidance, recognizing that clinicians should make recommendations that are best suited to meet the needs of individual patients.
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
RT @ZHeart11768530: 🔴 2023 ESH Hypertension Guidelines. What are the main recommendations? #openaccess https://t.co/33MHGFD0kE #medx #M…
-
-
Mashup Score: 42The optimal management of arterial blood pressure in acute stroke: A never-ending conundrum - 8 month(s) ago
Our understanding of the influence of blood pressure (BP) on the development of acute ischemic stroke and its significance in preventing further occurrences has prompted numerous researchers to investigate its impact on acute stroke outcomes. Despite numerous randomized controlled trials conducted over the years, the results have been inconclusive, indicating that addressing clinical inquiries necessitates revisiting the underlying pathophysiology. Consequently, the question of whether to manage BP during acute ischemic stroke remains contentious.
Source: www.ejinme.comCategories: General Medicine News, NeurologyTweet-
The optimal management of arterial blood pressure in acute stroke: A never-ending conundrum - European Journal of Internal Medicine https://t.co/OKbIDXFDdJ
-
-
Mashup Score: 3Albumin administration in internal medicine: A journey between effectiveness and futility - 10 month(s) ago
Human albumin is the most abundant circulating protein and accounts for approximately 50–60% of all total plasma proteins in healthy individuals. The molecule is composed of 585 amino acids organised into three homologous domains (I, II and III), each of which containing two distinct subdomains. The liver is the only site of production, with the hepatocytes entering into the blood circulation about 9–12 gs of albumin every day [1,2]. In physiological conditions, albumin synthesis involve only 20–30% of hepatocytes, therefore there is a large functional reserve allowing to increase it by 3–4 times when needed.
Source: www.ejinme.comCategories: General Medicine News, Hem/OncsTweet-
Albumin administration in internal medicine: A journey between effectiveness and futility https://t.co/PHMrgaKnIL via @enricop992 et al
-
-
Mashup Score: 51Residual cardiovascular risk: When should we treat it? - 1 year(s) ago
Cardiovascular disease (CVD) remains a major health problem worldwide and especially in the European Union (EU) with an incidence of 12.7 million new CVD cases per year, 2.2 million deaths in females and over 1.9 million deaths in males, thus being the most common cause of death in EU [1]. To date, and despite all the progress in understanding the impact of lifestyle habits (including new risk factors such as chronodisruption, dysbiosis or environmental pollution) on CVD risk, as well as the development of new lipid-lowering therapies, mainly targeting low-density lipoprotein cholesterol (LDL-C) as one of the main etiopathogenic factors of atherosclerosis and CVD, the reduction of the CVD risk burden ranges from 60 to 80 % in multiple randomized clinical trials (RCTs), with an increase of CVD events that can range between 2–3 % due to this residual risk if we consider the results of these studies in absolute values [2].
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
RT @ZHeart11768530: Residual Atherosclerotic Cardiovascular Disease Risk : Evaluation and Treatment https://t.co/IpxHKp2uci #cardiology #C…
-
-
Mashup Score: 13De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy? - 1 year(s) ago
Since more than two decades, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is considered the gold standard for patients with acute coronary syndrome (ACS) as well as for those with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) [1]. The more potent P2Y12 inhibitors prasugrel and ticagrelor have shown to reduce ischemic events at the cost of increased bleeding compared with clopidogrel [2,3]. Therefore, a 12-month DAPT with potent P2Y12 inhibitors represents the standard-of-care after ACS and may be considered after PCI in CCS patients in specific high ischemic risk situations [4–6].
Source: www.ejinme.comCategories: General Medicine News, CardiologistsTweet-
These data are on line with RCT even if I’m surprised that unguided De Escalation does better than guided. @luigispadafora @gbiondizoccai @DocSavageTJU @jpcostabel @MattiaGalli10 @SaDeRosa @FeliceGragnano @pabeda1 et al https://t.co/S9rtR49Zeb
-
-
Mashup Score: 6A new strategy for anticoagulation: The factor XI inhibitors - 1 year(s) ago
In the last decade, new oral anticoagulant agents with a direct inhibition of specific clotting factors (DOACs) have been claimed as first-choice therapy for the prevention of cardioembolic events in patients with atrial fibrillation and for the treatment of venous thromboembolism (VTE) thanks to improved safety and ease of use in comparison to vitamin K antagonists (VKAs) [1,2].
Source: www.ejinme.comCategories: General Medicine News, Hem/OncsTweet-
A new strategy for anticoagulation: The factor XI inhibitors - European Journal of Internal Medicine https://t.co/eyzoOj7VSV
-
https://t.co/qxrXI4SpSf